紫杉醇-卡铂联合贝伐珠单抗及贝伐珠单抗维持治疗用于转移性、复发性和持续性子宫颈癌:一项开放标签多中心II期试验(JGOG1079)
这项多中心开放标签II期研究评估紫杉醇-卡铂联合贝伐珠单抗及贝伐珠单抗维持治疗用于转移性、复发性和持续性子宫颈癌的疗效与安全性。69例患者接受紫杉醇175 mg/m2、卡铂AUC 5、贝伐珠单抗15 mg/m2每三周一次,中位无进展生存期11.3个月,客观缓解率79.7%,接受维持治疗者中位无进展生存期14.3个月。
要点
- 中位无进展生存期11.3个月,客观缓解率79.7%(16例完全缓解,39例部分缓解)。
- 接受贝伐珠单抗维持治疗者中位无进展生存期14.3个月,未接受者7.4个月(p=0.0449)。
- 胃肠道穿孔/瘘发生4例(5.6%),均有放疗史。
核心结论
- 紫杉醇-卡铂联合贝伐珠单抗治疗是晚期或复发性子宫颈癌可接受且可耐受的治疗方案。
研究设计与样本
- 多中心、开放标签、II期研究,纳入不适合手术或放疗等局部治疗且未接受过全身化疗的可测量病灶患者,共分析69例。
- 方案为紫杉醇175 mg/m2、卡铂AUC 5、贝伐珠单抗15 mg/m2每三周一次,直至疾病进展或出现不可接受的不良事件。
- 主要终点为无进展生存期,次要终点为客观缓解率、总生存期、安全性和治疗失败时间。
主要发现
- 中位紫杉醇-卡铂治疗持续6个周期,40%的患者接受了贝伐珠单抗维持治疗。
- 中位无进展生存期11.3个月,中位总生存期未达到,中位治疗失败时间5.9个月。
- 客观缓解率79.7%(95%CI 63.8-88.4),其中完全缓解16例(23.2%),部分缓解39例(56.5%)。
- 接受维持治疗的25例患者中位无进展生存期14.3个月(95%CI 7.3-17个月),未接受维持治疗者为7.4个月(95%CI 6.1-11个月),p=0.0449。
- 胃肠道穿孔/瘘发生4例(5.6%),均有放疗史。
临床怎么用
- 原文结论认为紫杉醇-卡铂联合贝伐珠单抗治疗是晚期或复发性子宫颈癌可接受且可耐受的治疗方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This multicenter, open-label, phase II study aimed to evaluate the efficacy and safety of paclitaxel-carboplatin, bevacizumab, and bevacizumab-based maintenance therapy for metastatic, recurrent, and persistent uterine cervical cancer. METHODS: Patients with measurable diseases that were not adapted to regional therapies, such as surgery or radiotherapy, and were systematic chemotherapy-naïve were eligible. The participants received paclitaxel (175 mg/m2), carboplatin (AUC 5), and bevacizumab (15 mg/m2) every three weeks until disease progression or unacceptable adverse events occurred. The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall response rate (ORR), overall survival (OS), safety, and time to treatment failure. RESULTS: Sixty-nine patients were analyzed using our protocol. The median paclitaxel- carboplatin therapy duration was six cycles; 40% of patients received bevacizumab maintenance therapy. The median PFS was 11.3 months. The median OS was not reached; the median time to treatment failure was 5.9 months. The ORR was 79.7% [95% confidence interval (CI) 63.8-88.4]; 16 patients (23.2%) showed complete response (CR) and 39 patients (56.5%) showed partial response (PR). The median PFS was 14.3 months (95% CI 7.3-17 months) for the 25 patients who received maintenance therapy and 7.4 months (95% CI 6.1-11 months) for nonrecipients (p = 0.0449). Gastrointestinal perforation/fistulas occurred in four patients (5.6%), all of whom had a history of radiation therapy. CONCLUSIONS: Paclitaxel-carboplatin and bevacizumab therapy is an acceptable and tolerable treatment for advanced or recurrent cervical cancer.
引用
- Tanigawa T, Takeshima N, Ishikawa H, et al. Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079). Gynecol Oncol. 2022. PMID: 35487773. doi:10.1016/j.ygyno.2022.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。